Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan
March 30, 2020
- Daiichi Sankyo Shares Anti-Coronavirus Measures, Development Plan
March 30, 2020
- Daiichi Sankyo, Kitasato Pharma End Flu Vaccine Collaboration
March 30, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
- US FDA Accepts Xofluza’s Granule Version, Pediatric Use for Review: Shionogi
March 30, 2020
- Kissei Licenses CG Oncology's Oncolytic Viral Therapy in Asia Excluding China
March 30, 2020
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- Eisai Files CTCL/PTCL Drug at MHLW Request
March 27, 2020
- Yoshindo Curbs Shipments of Tranexamic Acid as Coronavirus Hits API Supplies
March 27, 2020
- Ono, BMS Submit Opdivo/Yervoy Duo for NSCLC in Combination with Chemo
March 27, 2020
- Takeda to Introduce Fronteo’s Drug Discovery Support AI System
March 27, 2020
- Roche Diagnostics Files New Coronavirus Test in Japan
March 27, 2020
- Pfizer Japan Extends Voluntary Ban on Doctor Visits to April 10
March 27, 2020
- Otsuka’s PDE4 Inhibitor Difamilast Delivers Positive Data for Atopic Dermatitis in Japan PIII
March 27, 2020
- COVID-19-Disrupted Air Freight Hitting Commodity Transports, but No Major Impact So Far on Drugs
March 26, 2020
- Fujifilm Launches Contract Services for Process Development, Manufacturing of Liposome Formulations
March 26, 2020
- Asahi Kasei’s US Subsidiary Turbocharges Ventilator Production amid Coronavirus Outbreak
March 26, 2020
- Face Mask Shortages Crippling Drug Makers’ Business Activities, Travel Restrictions Could Delay Approval
March 26, 2020
- Aspen Japan President to Lead Sandoz K.K.
March 26, 2020
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…